 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- | pegylated human adrenomedullin (HM201) / Himuka AM Pharma
Trial completion, Trial primary completion date: Assessment of the Safety, Tolerability, and Pharmacokinetic of HM201 (clinicaltrials.gov) - Feb 1, 2023
P1, N=53, Completed, Sponsor: Syneos Health
Recruiting --> Completed | Trial primary completion date: Aug 2022 --> Dec 2022
- | pegylated human adrenomedullin (HM201) / Himuka AM Pharma
Enrollment open: Assessment of the Safety, Tolerability, and Pharmacokinetic of HM201 (clinicaltrials.gov) - Apr 26, 2022
P1, N=68, Recruiting, Sponsor: Syneos Health
Recruiting --> Completed | Trial primary completion date: Aug 2022 --> Dec 2022 Not yet recruiting --> Recruiting
- | pegylated human adrenomedullin (HM201) / Himuka AM Pharma
New P1 trial: Assessment of the Safety, Tolerability, and Pharmacokinetic of HM201 (clinicaltrials.gov) - Oct 20, 2021
P1, N=68, Not yet recruiting, Sponsor: Syneos Health